Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8P1Q

USP28 in complex with FT206

Summary for 8P1Q
Entry DOI10.2210/pdb8p1q/pdb
DescriptorUbiquitin carboxyl-terminal hydrolase 28, DIMETHYL SULFOXIDE, 3-azanyl-N-[(2S)-6-[(1S,5R)-3,8-diazabicyclo[3.2.1]octan-3-yl]-1,2,3,4-tetrahydronaphthalen-2-yl]-6-methyl-thieno[2,3-b]pyridine-2-carboxamide, ... (4 entities in total)
Functional Keywordsusp28, dub, ubiquitin, cancer, oncoprotein
Biological sourceHomo sapiens (human)
More
Total number of polymer chains2
Total formula weight116817.74
Authors
Sauer, F.,Karal Nair, R.,Kisker, C. (deposition date: 2023-05-12, release date: 2024-05-22, Last modification date: 2024-12-04)
Primary citationPatzke, J.V.,Sauer, F.,Nair, R.K.,Endres, E.,Proschak, E.,Hernandez-Olmos, V.,Sotriffer, C.,Kisker, C.
Structural basis for the bi-specificity of USP25 and USP28 inhibitors.
Embo Rep., 25:2950-2973, 2024
Cited by
PubMed Abstract: The development of cancer therapeutics is often hindered by the fact that specific oncogenes cannot be directly pharmaceutically addressed. Targeting deubiquitylases that stabilize these oncogenes provides a promising alternative. USP28 and USP25 have been identified as such target deubiquitylases, and several small-molecule inhibitors indiscriminately inhibiting both enzymes have been developed. To obtain insights into their mode of inhibition, we structurally and functionally characterized USP28 in the presence of the three different inhibitors AZ1, Vismodegib and FT206. The compounds bind into a common pocket acting as a molecular sink. Our analysis provides an explanation why the two enzymes are inhibited with similar potency while other deubiquitylases are not affected. Furthermore, a key glutamate residue at position 366/373 in USP28/USP25 plays a central structural role for pocket stability and thereby for inhibition and activity. Obstructing the inhibitor-binding pocket by mutation of this glutamate may provide a tool to accelerate future drug development efforts for selective inhibitors of either USP28 or USP25 targeting distinct binding pockets.
PubMed: 38816515
DOI: 10.1038/s44319-024-00167-w
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.79 Å)
Structure validation

236620

PDB entries from 2025-05-28

PDB statisticsPDBj update infoContact PDBjnumon